European biotech startup Cradle raised $24 million, gaining funds for its effort to use AI to help scientists design and engineer proteins faster and more cost-effectively.

Index Ventures and Kindred Capital participated in the Series A round, along with Chris Gibson, the co-founder of Recursion Pharmaceuticals Inc., and Tom Glocer, the former chief executive officer of Thomson Reuters Corp. and a Merck & Co. board member, Cradle said Tuesday. The startup has raised a total of $33 million so far, including a seed round last year.